Smith & Nephew Plc (LON:SN, NYSE: SNN), the global medical technology company, has announced that David King will join the Board as an independent Non-Executive Director with effect from 1 July 2025. David will serve as a member of the Compliance & Culture and the Remuneration Committees.
David is currently CEO, executive director and chair of Fortis Life Sciences. He also serves, or has recently served, as a Chair or non-executive director on the boards of several US healthcare companies including ZimVie (2022 – 2025), VaxCare (2021 – 2025), Privia Health, Health Channels, LGC and AmSurg Corporation. David served as executive chair and CEO for Laboratory Corporation of America (LabCorp) from 2007 to 2020 and prior to that was a partner at Hogan & Hartson LLP (now Hogan Lovells).
Rupert Soames, Chair of Smith & Nephew, commented:
“We are delighted to welcome David to our Board. He has extensive experience in the healthcare and life sciences sectors helping to transform and grow businesses in the US and globally.”
